US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

New paper using Attana technology for development of therapeutic antibodies against cancer

We are very happy that Attana technology has more or less from the start been involved in taking a malaria parasite protein towards a generic cancer treatment!   The latest work, published in Nature Communications  describes that translation into clinical trials turned out to be complicate e.g. by complex manufacturing and expensive scale-up processes of the malaria protein. Converting it into antibodies turned out to be the trick.   Antibody manufacturing is significantly less complicated than protein manufacturing. Attana

BioInvent evaluating Attana Technology

BioInvent and Attana has signed a three-month evaluation agreement. BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology and antibody biology, BioInvent generates innovative immuno-oncology drug candidates.Attana will in May install Attana Cell™ 250 instrument and train users at BioInvents labs in Lund. During the evaluation period cell- and sera-based assays will be performed to study interactions between antibodies and target cells.

One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k

The company's strategy to strengthen its position and establish strong relationships with five reference customers in the USA has now resulted in one of the country's leading health institutes ordering an upgrade from their Attana Cell™ 200 to Attana Cell™ 250. The order will impact Q1 results and Q2 cashflow.The purpose of the upgrade is to streamline ongoing research projects. The primary goal for the customer is to enhance palliative care for cancer patients by donating T-cells from healthy individuals to the patients. The Company's technology is utilized to study interactions between

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

In the paper in "Journal of Colloid And Interface Science ", the Attana quartz crystal microbalance (QCM) is applied to study the electrical response of two ionic liquids. Controlled by an applied electric field, the structure and interaction of ionic liquids on the surface, can be monitored and optimized. This is of high importance for the development of e.g. environment friendly lubricants. This is the third paper by the team of Prof Rutland that demonstrates how Attana technology can be applied to monitor interaction

Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.

The customer develops therapeutic antibodies against cancer and uses Attana's cell-based technology to test and verify its drug candidates in as physically similar conditions as possible. As the target receptors are membrane proteins in the cancer cells, Attana's technology is the only technology that can perform this label-free (ie without fluorescence or similar tags). The alternatives with labeled molecules have generated results with poorer agreement with in-vivo experiments. Attana's technology speeds up and increases the precision of their development process and reduces their

New publication that shows the strength of Attana's offering in diagnostics, here applied in veterinary medicine.

In a new article published in Frontiers in Veterinary Science , the company Alertix Veterinary Diagnostics AB, in collaboration with several groups at the Swedish University of Agricultural Sciences, has published results for a diagnostic test for dogs having cancer. In 2019-2020, Attana performed contract research projects to select the optimal antibodies for this diagnostic test. The article states that the Alertix test has a higher sensitivity than the tests available on the market. The kinetics of the antibody

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics ". The project is coordinated by Prof. Ian Nicholls at Linnaeus University  in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.The aim of the project is to provide precise information about the medical conditions of

Attana enters the second year of a five-year service and support contract with a leading health institute in the US

We are now entering the second year of increased presence at the US. We are now stepping into the second year of a long-term agreement of full-service and support with one of our future reference sites. The coming 12 month we look forward to new users and upcoming exciting experiments enabled by the Attana platform. Read more here about the startup of the contract: 

Reversible sensor chips for real-time determination of protein– carbohydrate interactions on living cancer cells for the diagnosis and treatment of cancer

A new publication using Attana from the team of prof Zhichao Pei at the College of Chemistry & Pharmacy, Northwest A&F University, China. In this work, a novel dynamic reversible sensor surface to determine kinetics of protein-carbohydrate interactions suspension cancer cell surfaces using a Attana QCM technology has been developed.The group has applied Attana Cell[TM] 200 instrument and Attana standard sensor chips. However, they have modified the sensor surface chemistry in order to enable regeneration of the surface, that means practically that the cells can be exchange and more

Attana’s presentation from Småbolagsdagarna is now available on YouTube

On June 14, Attana attended Aktiespararna’s Småbolagsdagarna where CEO, Teodor Aastrup, gave a 20-minute-long presentation followed by a 10-minute-long Q&A.The presentation was held in Swedish and primarily focused on Attana’s history and milestones, followed by Attana’s ongoing work within both its business areas – Life Science and Diagnostics. The presentation concluded with Attana long-term, 2030 plan. The presentation can be accessed by following this link: Attana – Småbolagsdagarna 2022 

Attana has received a 5-year service and support contract from a leading health institute in the US

The order is a result of the strategic business plan that Attana launched prior to the Covid-19 pandemic, which has been on hold during the pandemic.The order is for a 5-year “Gold” service and support agreement and includes both technical support and maintenance as well as application and assay support. The order is a result of a strategic business plan that was initiated before the pandemic , which has, however, since been on hold. The first step of the plan is to revitalize a

New publication using Attana Technology for interaction studies of antibodies with extracellular vesicle

The characterization of extracellular vesicles interactions is important to gain understanding of several diseases. In this paper the universities in Helsinki and Karlstad have collaborated and used state of the art technology to analyse extracellular vesicles obtained from human blood plasma. The extracellular vesicles interaction with antibodies and transmembrane proteins were detailed characterized and hence opens up for increased understanding extracellular vesicles roles in several diseases.Extracellular vesicles (EVs) are nanosized lipid particles (50–3000nm) released from cells that

Updated track record demonstrates significantly increased success rate for drug candidates validated by Attana

Just over a year ago, a retroactive study was published on Attana´s track record in drug development in IBI (International Biopharmaceutical Industry), read the full article her e. Today, updated results were published and the number of analyzed candidates for Attana in the preclinical phase amounts to 103 compared to 77 just over a year ago. The validated candidates have come further in the development process today, and the success rate is still significantly higher

Attana receives a Cell™ 250 instrument order from a European Life Science company

Attana has received an order for a Cell™ 250 instrument from a European Life Science company. This is the client’s second Attana instrument and is the result of a successful use and the client’s growth plans.The Cell™ 250 instrument will be installed during Q1 2022 and will positively affect Attana earnings in Q1 2022 and cash flow for the remainder of the year. “We strive to be close partner with our clients. This order is a result of this and our ability to grow together with our clients. We see good potential in increased further collaboration” comments Teodor Aastrup, CEO Attana.

Attana and AroCell initiates discussion for collaboration

Attana can today announce that the company has initiated a discussion about a new collaboration with the in vitro diagnostics company AroCell AB (Publ).AroCell AB is a Swedish company that develops and markets blood and urine sample tests and specializes in oncology and bacteriology. The company has a broad product portfolio that is used in healthcare and is established in various markets. The collaboration aims to exchange valuable knowledge in quality and product development, while AroCell's biomarkers can eventually be used on Attana's instruments. Teodor Aastrup, CEO Attana comments:

Attana’s presentation from Biotech Showcase 2022 is now available on Attana’s website

January 10–19, Attana is participating in one of the largest biotech conferences in the world – Biotech Showcase. Attana is attending the digital conference and have published a presentation as well as participated in digital one-to-one meetings.The presentation was held in English and primarily focused on Attana’s ongoing diagnostic work and its two business units – Life Science and Diagnostics. The presentation can be accessed on Attana’s website by following this link: Attana – Biotech Showcase 2022 

Update following Attana’s participation at the Drug Discovery V-Forum

On April 21, Attana participated in the conference Drug Discovery V-Forum to present the company and listen in to presentations from other companies within the Life Science industry.This marked yet another conference where Attana had the opportunity to communicate its products and services to potential customers and partners. The company also presented preliminary results from the ongoing work with Attana Diagnostics and the development of a SARS-CoV-2 immunoassay. Attana’s recorded presentation can be found here .

Retrospective study on Attana’s track record published in IBI shows extraordinary results

Today, a retrospective study on Attana’s track record was published in IBI (International Biopharmaceutical Industry). The study evaluates the outcome of all the 77 drug candidates Attana has analyzed for customers in the pre-clinical phase.The result of the study shows Attana has had an accuracy of 100% in determining which candidates will succeed in clinical trials, outperforming the company’s previously communicated expectations. The findings suggest that Attana’s proprietary technology and validation process has improved clinical trial success rates by over 80%. If the accuracy of the

Five new scientific publications enabled by Attana

Five new scientific articles featuring Attana instruments have recently been published in peer reviewed publications including the highly regarded Science Advances as well as Molecular Cancer Therapeutics, Talanta and Carbohydrate Research.The team of Professor Roland Kontermann at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany has published their work in the American Association for Cancer Research journal, Molecular Cancer Therapeutics. The article, Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and

Attana participates at the 11th Drug Discovery Innovation Programme, DDIP 2020, Munich April 23-24, 2020

The DDIP-conference focus on new technologies for improved drug development. At the conference leading professionals within industry and academy will participate. Attana will give a presentation at the scientific session and have an exhibition booth.Attana´s CEO Teodor Aastrup will give a presentation with focus on success cases where Attana’s 3[rd] generation biosensor has increased the efficiency in drug development. To learn more about the conference and the participants please read here. 

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe